Latest Price of Entrectinib in 2025

Entrectinib (Entrectinib) is a small molecule tyrosine kinase inhibitor, mainly used to treat patients with ROS1-positive non-small cell lung cancer (NSCLC) and patients with various solid tumors carrying NTRK gene fusions. Compared with traditional chemotherapy, entrectinib can block abnormal signaling pathways more specifically and inhibit the growth and spread of tumor cells at the molecular level. Especially for patients with clear driver genes, entrectinib can often bring higher remission rates and longer-lasting disease control periods, which is also an important manifestation of precision medicine.

Another clinical advantage of the drug is that it can penetrate the blood-brain barrier and also shows certain activity in patients with brain metastases. This is particularly important for patients with non-small cell lung cancer, because brain metastases are a common problem that affects prognosis. It is precisely because of this feature that entrectinib was quickly approved in many countries and regions around the world and became one of the representative drugs for molecular classification precision treatment.

In terms of price, entrectinib is available in capsule form and has been included in the medical insurance reimbursement list, which significantly reduces the financial burden on patients. The common specifications are 100mg, 30 tablets and 200mg, 90 tablets. Each box is priced at more than 20,000 yuan, and the actual out-of-pocket ratio of patients who meet the medical insurance conditions is relatively controllable. In comparison, the market price of the European version of the original drug is higher. Taking 90 tablets of 200 mg as an example, the price per box may be more than 40,000 yuan, and the price will fluctuate due to exchange rate fluctuations. It is worth noting that generic drugs are already available in overseas markets. For example, the 100mg 60-tablet drug produced by a Lao pharmaceutical factory costs only about RMB 1,000 per box. The drug ingredients are basically the same as the original drug, so it has an advantage in terms of cost controllability.

Overall, the use of entrectinib is very clear, mainly targeting ROS1-positive lung cancer and NTRK fusion tumors. There is a large price gap between original drugs and generic drugs, and medical insurance reimbursement reduces the burden on patients.

Reference materials:https://www.roche.com/products/rozlytrek